RxDoctor Payments Data

Chelsey Winningham

Family · Longview, TXNPI 1083481139

Payments from drug & device makers

$508in general payments, 2019–2025

Across 29 payments — averaging $17.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$108
  • Novo Nordisk$90
  • AbbVie$67
  • Amgen$59
  • GSK$51
  • Madrigal Pharmaceuticals$23
  • plus $110 from 7 others

What the payments were for

  • Food & beverage$508100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$508 in reported general payments places this provider in the 55th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$70,374
Medicare patients
147
Services billed
1,511

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide82$92,248
OzempicSemaglutide45$48,129
EliquisApixaban35$39,133
JanuviaSitagliptin Phosphate21$26,839
JardianceEmpagliflozin15$22,296
FarxigaDapagliflozin Propanediol14$20,196
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$18,502
MyrbetriqMirabegron18$15,680
Breo ElliptaFluticasone/Vilanterol13$15,507
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$10,202
RybelsusSemaglutide12$10,161
Albuterol Sulfate HfaAlbuterol Sulfate161$5,508
Celecoxib27$3,058
Gabapentin144$2,914
Acetaminophen-CodeineAcetaminophen With Codeine90$2,523

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$19$92,24882 claims
Novo NordiskOzempic, Rybelsus$90$58,29057 claims
PfizerEliquis$17$39,13335 claims
GSKTrelegy Ellipta, Breo Ellipta$51$34,00838 claims
AstraZenecaFarxiga, Breztri Aerosphere$108$30,39828 claims
Boehringer IngelheimJardiance$14$22,29615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 15,456 family providers in Texas.

Other family in Longview

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →